TW200740804A - Glucokinase activators - Google Patents
Glucokinase activatorsInfo
- Publication number
- TW200740804A TW200740804A TW096102803A TW96102803A TW200740804A TW 200740804 A TW200740804 A TW 200740804A TW 096102803 A TW096102803 A TW 096102803A TW 96102803 A TW96102803 A TW 96102803A TW 200740804 A TW200740804 A TW 200740804A
- Authority
- TW
- Taiwan
- Prior art keywords
- glucokinase
- glucokinase activators
- diseases
- underactivity
- prevention
- Prior art date
Links
- 102000030595 Glucokinase Human genes 0.000 title abstract 4
- 108010021582 Glucokinase Proteins 0.000 title abstract 4
- 239000012190 activator Substances 0.000 title 1
- 206010011953 Decreased activity Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76317306P | 2006-01-27 | 2006-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200740804A true TW200740804A (en) | 2007-11-01 |
Family
ID=38109991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW096102803A TW200740804A (en) | 2006-01-27 | 2007-01-25 | Glucokinase activators |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8022222B2 (enExample) |
| EP (1) | EP1986645B1 (enExample) |
| JP (1) | JP5236499B2 (enExample) |
| CN (1) | CN101437512A (enExample) |
| AT (1) | ATE539748T1 (enExample) |
| CA (1) | CA2637172A1 (enExample) |
| ES (1) | ES2378704T3 (enExample) |
| TW (1) | TW200740804A (enExample) |
| WO (1) | WO2007089512A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8431713B2 (en) | 2007-01-24 | 2013-04-30 | Array Biopharma, Inc. | 2-aminopyridine derivatives as glucokinase activators |
| CA2681695A1 (en) * | 2007-03-23 | 2008-10-02 | Array Biopharma Inc. | 2-aminopyridine analogs as glucokinase activators |
| WO2009022171A1 (en) * | 2007-08-13 | 2009-02-19 | Astrazeneca Ab | Pyridinyiioxy pyridines as alk5 inhibitors |
| WO2009022179A2 (en) * | 2007-08-14 | 2009-02-19 | Astrazeneca Ab | Glucokinase activators in the treatment of osteoarthritis |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| UA101166C2 (ru) | 2007-09-21 | 2013-03-11 | Аррей Биофарма Инк. | Производные пиридин-2-иламино-1,2,4-тиадиазола как активаторы глюкокиназы для лечения сахарного диабета |
| EA201000561A1 (ru) | 2007-10-09 | 2010-10-29 | Мерк Патент Гмбх | Производные пиридина, пригодные в качестве активаторов глюкокиназы |
| US8558000B2 (en) | 2008-01-23 | 2013-10-15 | Bristol-Myers Squibb Company | 4-pyridinone compounds and their use for cancer |
| US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
| KR20110070887A (ko) | 2008-10-02 | 2011-06-24 | 레스피버트 리미티드 | Ｐ38 엠에이피 키나제 억제제 |
| JPWO2010058846A1 (ja) | 2008-11-21 | 2012-04-19 | アステラス製薬株式会社 | ４，６−ジアミノニコチンアミド化合物 |
| JP5670912B2 (ja) | 2008-12-11 | 2015-02-18 | レスピバート・リミテツド | ｐ３８ＭＡＰキナーゼ阻害剤 |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| GB0921730D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Method of treatment |
| GB0921731D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Theraputic uses |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2553086B1 (en) | 2010-03-31 | 2017-04-19 | The Scripps Research Institute | Reprogramming cells |
| GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
| EP2556067B1 (en) | 2010-04-08 | 2016-02-24 | Respivert Limited | Pyrazolyl ureas as p38 map kinase inhibitors |
| EP2556068B1 (en) | 2010-04-08 | 2019-01-23 | Respivert Limited | P38 map kinase inhibitors |
| US8178689B2 (en) | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| HUE037860T2 (hu) * | 2010-11-19 | 2018-09-28 | Ligand Pharm Inc | Heterociklusos aminok és alkalmazásuk |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| JPWO2012121314A1 (ja) * | 2011-03-09 | 2014-07-17 | 第一三共株式会社 | ジピリジルアミン誘導体 |
| CN102786517B (zh) * | 2011-05-18 | 2017-06-06 | 中国医学科学院药物研究所 | Gk和ppar双重激动活性的嘧啶噻唑胺类衍生物 |
| JP5748210B2 (ja) * | 2011-05-26 | 2015-07-15 | 日本化薬株式会社 | 複素環化合物の製造方法 |
| EA031153B1 (ru) | 2011-06-10 | 2018-11-30 | Мерк Патент Гмбх | Применение пиримидиновых соединений с btk ингибирующей активностью |
| EP2754654B1 (en) * | 2011-09-05 | 2018-05-30 | Chugai Seiyaku Kabushiki Kaisha | Method for producing coumarin derivative |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013086397A1 (en) * | 2011-12-08 | 2013-06-13 | Array Biopharma Inc. | Urea compounds as gka activators |
| US9296735B2 (en) | 2012-05-18 | 2016-03-29 | Amgen Inc. | Method for the preparation of thiadiazoles |
| US9546153B2 (en) * | 2012-11-08 | 2017-01-17 | Bristol-Myers Squibb Company | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators |
| WO2014076484A1 (en) | 2012-11-16 | 2014-05-22 | Respivert Limited | Kinase inhibitors |
| US20160031874A1 (en) | 2013-03-13 | 2016-02-04 | The Broad Institute, Inc. | Substituted aminothiazoles for the treatment of tuberculosis |
| WO2016001341A1 (en) * | 2014-07-03 | 2016-01-07 | F. Hoffmann-La Roche Ag | Sulfonylaminopyridine compounds, compositions and methods of use |
| CN104610143A (zh) * | 2015-02-12 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 一种含硝基喹啉结构的葡萄糖激酶活化剂及其用途 |
| JP6483272B2 (ja) * | 2015-02-17 | 2019-03-13 | グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス，チャイニーズ アカデミー オブ サイエンスィズ | 白色脂肪組織の褐色化を誘導するための化合物および方法 |
| US10807983B2 (en) | 2015-03-16 | 2020-10-20 | Ligand Pharmaceuticals, Inc. | Imidazo-fused heterocycles and uses thereof |
| CN107690429B (zh) * | 2015-04-07 | 2022-02-25 | Ela制药有限公司 | 用于治疗和/或预防细胞或组织坏死的组合物，其特异性靶向组织蛋白酶c和/或cela1和/或cela3a和/或与其结构相关的酶 |
| CA2988405A1 (en) | 2015-06-11 | 2016-12-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | P62-zz chemical inhibitor |
| US10894784B2 (en) | 2015-12-18 | 2021-01-19 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
| WO2017207534A1 (en) | 2016-06-03 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted heteroarylbenzimidazole compounds |
| CN115448916B (zh) * | 2016-10-14 | 2026-04-28 | 武田药品工业株式会社 | Tyk2抑制剂及其用途 |
| EP3846793B1 (en) | 2018-09-07 | 2024-01-24 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| CN113993859B (zh) * | 2019-06-25 | 2024-07-02 | 益方生物科技(上海)股份有限公司 | 杂环化合物、其制备方法及其使用方法 |
| CN110898049B (zh) * | 2019-11-29 | 2021-09-14 | 华中师范大学 | 二硫化合物在制备药物中的应用、fbp酶抑制剂及用于预防和/或治疗糖尿病的药剂 |
| MX2022010944A (es) | 2020-03-03 | 2022-11-09 | Pic Therapeutics Inc | Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos. |
| WO2022147694A1 (en) * | 2021-01-06 | 2022-07-14 | Beijing Erai Therapeutics Co., Ltd. | Aminoheteroaryl compounds and uses thereof |
| JP2024532276A (ja) | 2021-08-25 | 2024-09-05 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
| TW202315621A (zh) | 2021-08-25 | 2023-04-16 | 美商皮克醫療公司 | Ｅｉｆ４ｅ抑制劑及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0013899A (pt) | 1999-09-10 | 2003-07-08 | Merck & Co Inc | Composto, composição farmacêutica, processos de tratamento ou prevenção de câncer, de uma doença em que a angiogênese esteja implicada, da vascularização retinal, da retinopatia diabética, da degeneração macular relacionada a idade, de doenças inflamatórias, de uma doença ou condições dependentes da tirosina quinase, de patologias associadas com ossos, e, processos para produzir uma composição farmacêutica, e de reduzir ou prevenir dano tecidual em seguida a um evento isquêmico cerebral |
| AU2002346053B2 (en) | 2001-06-22 | 2008-03-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| ES2289279T3 (es) * | 2002-03-15 | 2008-02-01 | Vertex Pharmaceuticals Incorporated | Composiciones utiles como inhibidores de proteinquinasas. |
| US20040023981A1 (en) * | 2002-07-24 | 2004-02-05 | Yu Ren | Salt forms with tyrosine kinase activity |
| US20040023978A1 (en) * | 2002-07-24 | 2004-02-05 | Yu Ren | Active salt forms with tyrosine kinase activity |
| MXPA05003559A (es) | 2002-10-03 | 2005-06-03 | Novartis Ag | (tiazol-2-il)-amida o sulfonamida substituida como activadores de glicocinasa utiles en el tratamiento de diabetes de tipo 2. |
| AU2003285007A1 (en) * | 2002-10-30 | 2004-06-07 | Merck & Co., Inc. | Kinase inhibitors |
| PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| GB0328178D0 (en) * | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Compounds |
| CN1956982A (zh) | 2004-05-21 | 2007-05-02 | 万有制药株式会社 | 具有氨基噻唑骨架的Cdk4、6选择性抑制剂 |
| TWI378925B (en) * | 2005-01-14 | 2012-12-11 | Gilead Connenticut Inc | Certain substituted ureas as modulators of kinase activity |
| JP2008528585A (ja) * | 2005-01-26 | 2008-07-31 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| JP2008543754A (ja) * | 2005-06-09 | 2008-12-04 | メルク エンド カムパニー インコーポレーテッド | チェックポイントキナーゼの阻害剤 |
-
2007
- 2007-01-24 ES ES07716991T patent/ES2378704T3/es active Active
- 2007-01-24 AT AT07716991T patent/ATE539748T1/de active
- 2007-01-24 JP JP2008552395A patent/JP5236499B2/ja not_active Expired - Fee Related
- 2007-01-24 US US12/161,366 patent/US8022222B2/en not_active Expired - Fee Related
- 2007-01-24 WO PCT/US2007/001956 patent/WO2007089512A1/en not_active Ceased
- 2007-01-24 EP EP07716991A patent/EP1986645B1/en not_active Not-in-force
- 2007-01-24 CN CNA2007800107261A patent/CN101437512A/zh active Pending
- 2007-01-24 CA CA002637172A patent/CA2637172A1/en not_active Abandoned
- 2007-01-25 TW TW096102803A patent/TW200740804A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009524670A (ja) | 2009-07-02 |
| US20090247526A1 (en) | 2009-10-01 |
| EP1986645B1 (en) | 2012-01-04 |
| EP1986645A1 (en) | 2008-11-05 |
| CN101437512A (zh) | 2009-05-20 |
| US8022222B2 (en) | 2011-09-20 |
| WO2007089512A1 (en) | 2007-08-09 |
| ES2378704T3 (es) | 2012-04-17 |
| CA2637172A1 (en) | 2007-08-09 |
| JP5236499B2 (ja) | 2013-07-17 |
| ATE539748T1 (de) | 2012-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG170775A1 (en) | 2 -aminopyridine analogs as glucokinase activators | |
| WO2008118718A3 (en) | 2-aminopyridine analogs as glucokinase activators | |
| ATE521608T1 (de) | Glucokinaseaktivatoren | |
| PH12016501607B1 (en) | Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia | |
| WO2006091459A3 (en) | Compositions and methods for treating vascular permeability | |
| MX2010003117A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
| PL2134704T3 (pl) | Związki i kompozycje pełniące rolę modulatorów aktywności GPR119 | |
| TW200608979A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| GB2463833A (en) | Methods and compositions for the treatment of neurological disorders | |
| CR11383A (es) | Derivados piridin-2-il-amino-1,2,4 -tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus | |
| WO2010029089A3 (en) | Combination therapy for the treatment of diabetes and related conditions | |
| WO2006135915A3 (en) | Methods and compositions for treating degenerative bone disorders | |
| MY145070A (en) | Imidazolothiazole compounds for the treatment of disease | |
| MX2012000034A (es) | Metodos para el tratamiento o la prevencion de la fatiga. | |
| WO2008137633A3 (en) | Methods of modulating cellular homeostatic pathways and cellular survival | |
| WO2011065982A3 (en) | Polymorphisms associated with parkinson's disease | |
| MX2010010317A (es) | Compuestos heterociclicos novedosos y usos de los mismos. | |
| PH12013500808A1 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
| ATE480255T1 (de) | Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen | |
| MX2007005590A (es) | Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas. | |
| MY147247A (en) | Organic compounds and their uses | |
| ATE539748T1 (de) | Glucokinaseaktivatoren | |
| WO2007098091A3 (en) | Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs | |
| WO2010088450A3 (en) | Arylamide derivatives useful in the treatment of diseases associated with serca activity | |
| WO2008033440A3 (en) | Treatment of hyperproliferative diseases with anthraquinones |